Is IMNM or CLYM more profitable?

Climb Bio's return on equity of -31.45% beat Immunome's return on equity. Company Net Margins Return on Equity Return on Assets Immunome N/A -51.15% -47.32% Climb Bio N/A -31.45% -30.39%

Does the media refer more to IMNM or CLYM?

In the previous week, Climb Bio had 2 more articles in the media than Immunome. MarketBeat recorded 5 mentions for Climb Bio and 3 mentions for Immunome. Climb Bio's average media sentiment score of 0.27 beat Immunome's score of 0.25 indicating that Climb Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immunome 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Climb Bio 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to CLYM or ADPT?

In the previous week, Adaptive Biotechnologies had 5 more articles in the media than Climb Bio. MarketBeat recorded 10 mentions for Adaptive Biotechnologies and 5 mentions for Climb Bio. Adaptive Biotechnologies' average media sentiment score of 1.51 beat Climb Bio's score of 0.27 indicating that Adaptive Biotechnologies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Climb Bio 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Adaptive Biotechnologies 7 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Which has better valuation & earnings, ELVN or CLYM?

Enliven Therapeutics is trading at a lower price-to-earnings ratio than Climb Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Enliven Therapeutics N/A N/A -$103.69M -$1.67 N/A Climb Bio N/A N/A -$59.85M -$0.78 N/A

Is ELVN or CLYM more profitable?

Enliven Therapeutics' return on equity of -21.04% beat Climb Bio's return on equity. Company Net Margins Return on Equity Return on Assets Enliven Therapeutics N/A -21.04% -20.41% Climb Bio N/A -31.45% -30.39%

Does the media prefer ELVN or CLYM?

In the previous week, Enliven Therapeutics and Enliven Therapeutics both had 5 articles in the media. Climb Bio's average media sentiment score of 0.27 beat Enliven Therapeutics' score of 0.08 indicating that Climb Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Enliven Therapeutics 0 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Climb Bio 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to RARE or CLYM?

In the previous week, Ultragenyx Pharmaceutical had 3 more articles in the media than Climb Bio. MarketBeat recorded 8 mentions for Ultragenyx Pharmaceutical and 5 mentions for Climb Bio. Ultragenyx Pharmaceutical's average media sentiment score of 0.47 beat Climb Bio's score of 0.27 indicating that Ultragenyx Pharmaceutical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ultragenyx Pharmaceutical 4 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Climb Bio 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better valuation and earnings, CLYM or KOD?

Climb Bio is trading at a lower price-to-earnings ratio than Kodiak Sciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Climb Bio N/A N/A -$59.85M -$0.78 N/A Kodiak Sciences N/A N/A -$229.97M -$4.17 N/A

Is CLYM or KOD more profitable?

Climb Bio's return on equity of -31.45% beat Kodiak Sciences' return on equity. Company Net Margins Return on Equity Return on Assets Climb Bio N/A -31.45% -30.39% Kodiak Sciences N/A -253.85% -81.48%

Does the media refer more to CLYM or KOD?

In the previous week, Climb Bio had 2 more articles in the media than Kodiak Sciences. MarketBeat recorded 5 mentions for Climb Bio and 3 mentions for Kodiak Sciences. Kodiak Sciences' average media sentiment score of 0.51 beat Climb Bio's score of 0.27 indicating that Kodiak Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Climb Bio 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Kodiak Sciences 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Climb Bio (CLYM) Competitors

$10.77 +0.22 (+2.09%)

Closing price 04:00 PM Eastern

Extended Trading

$10.98 +0.22 (+2.00%)

As of 06:52 PM Eastern

Compare

CLYM vs. IMNM, ADPT, ELVN, RARE, and KOD

Should you buy Climb Bio stock or one of its competitors? MarketBeat compares Climb Bio with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Climb Bio include Immunome (IMNM), Adaptive Biotechnologies (ADPT), Enliven Therapeutics (ELVN), Ultragenyx Pharmaceutical (RARE), and Kodiak Sciences (KOD). These companies are all part of the "pharmaceutical products" industry.

How does Climb Bio compare to Immunome?

Immunome (NASDAQ:IMNM) and Climb Bio (NASDAQ:CLYM) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, profitability, valuation, institutional ownership, dividends, risk and earnings.

Climb Bio's return on equity of -31.45% beat Immunome's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunome	N/A	-51.15%	-47.32%
Climb Bio	N/A	-31.45%	-30.39%

Immunome currently has a consensus target price of $33.17, suggesting a potential upside of 78.22%. Climb Bio has a consensus target price of $21.64, suggesting a potential upside of 100.89%. Given Climb Bio's stronger consensus rating and higher probable upside, analysts clearly believe Climb Bio is more favorable than Immunome.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunome	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.85
Climb Bio	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	3 Strong Buy rating(s)	3.07

44.6% of Immunome shares are owned by institutional investors. Comparatively, 69.8% of Climb Bio shares are owned by institutional investors. 7.2% of Immunome shares are owned by insiders. Comparatively, 2.6% of Climb Bio shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Climb Bio had 2 more articles in the media than Immunome. MarketBeat recorded 5 mentions for Climb Bio and 3 mentions for Immunome. Climb Bio's average media sentiment score of 0.27 beat Immunome's score of 0.25 indicating that Climb Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immunome	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Climb Bio	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Immunome has a beta of 2.04, suggesting that its stock price is 104% more volatile than the broader market. Comparatively, Climb Bio has a beta of 0.09, suggesting that its stock price is 91% less volatile than the broader market.

Climb Bio has lower revenue, but higher earnings than Immunome. Climb Bio is trading at a lower price-to-earnings ratio than Immunome, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunome	$6.94M	303.69	-$212.39M	-$2.38	N/A
Climb Bio	N/A	N/A	-$59.85M	-$0.78	N/A

Summary

Climb Bio beats Immunome on 10 of the 15 factors compared between the two stocks.

How does Climb Bio compare to Adaptive Biotechnologies?

Climb Bio (NASDAQ:CLYM) and Adaptive Biotechnologies (NASDAQ:ADPT) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, valuation, profitability, media sentiment, institutional ownership, analyst recommendations, dividends and risk.

Climb Bio presently has a consensus price target of $21.64, indicating a potential upside of 100.89%. Adaptive Biotechnologies has a consensus price target of $19.57, indicating a potential upside of 17.19%. Given Climb Bio's stronger consensus rating and higher probable upside, research analysts plainly believe Climb Bio is more favorable than Adaptive Biotechnologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Climb Bio	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	3 Strong Buy rating(s)	3.07
Adaptive Biotechnologies	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Climb Bio has a net margin of 0.00% compared to Adaptive Biotechnologies' net margin of -16.82%. Climb Bio's return on equity of -31.45% beat Adaptive Biotechnologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Climb Bio	N/A	-31.45%	-30.39%
Adaptive Biotechnologies	-16.82%	-40.06%	-16.64%

Adaptive Biotechnologies has higher revenue and earnings than Climb Bio. Adaptive Biotechnologies is trading at a lower price-to-earnings ratio than Climb Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Climb Bio	N/A	N/A	-$59.85M	-$0.78	N/A
Adaptive Biotechnologies	$276.98M	9.65	-$59.50M	-$0.33	N/A

69.8% of Climb Bio shares are owned by institutional investors. Comparatively, 99.2% of Adaptive Biotechnologies shares are owned by institutional investors. 2.6% of Climb Bio shares are owned by company insiders. Comparatively, 5.7% of Adaptive Biotechnologies shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Adaptive Biotechnologies had 5 more articles in the media than Climb Bio. MarketBeat recorded 10 mentions for Adaptive Biotechnologies and 5 mentions for Climb Bio. Adaptive Biotechnologies' average media sentiment score of 1.51 beat Climb Bio's score of 0.27 indicating that Adaptive Biotechnologies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Climb Bio	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Adaptive Biotechnologies	7 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Climb Bio has a beta of 0.09, indicating that its share price is 91% less volatile than the broader market. Comparatively, Adaptive Biotechnologies has a beta of 2.16, indicating that its share price is 116% more volatile than the broader market.

Summary

Adaptive Biotechnologies beats Climb Bio on 9 of the 16 factors compared between the two stocks.

How does Climb Bio compare to Enliven Therapeutics?

Enliven Therapeutics (NASDAQ:ELVN) and Climb Bio (NASDAQ:CLYM) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, media sentiment, risk, institutional ownership, analyst recommendations, earnings, valuation and profitability.

Enliven Therapeutics has a beta of 0.29, meaning that its share price is 71% less volatile than the broader market. Comparatively, Climb Bio has a beta of 0.09, meaning that its share price is 91% less volatile than the broader market.

95.1% of Enliven Therapeutics shares are held by institutional investors. Comparatively, 69.8% of Climb Bio shares are held by institutional investors. 3.0% of Enliven Therapeutics shares are held by company insiders. Comparatively, 2.6% of Climb Bio shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Enliven Therapeutics is trading at a lower price-to-earnings ratio than Climb Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enliven Therapeutics	N/A	N/A	-$103.69M	-$1.67	N/A
Climb Bio	N/A	N/A	-$59.85M	-$0.78	N/A

Enliven Therapeutics' return on equity of -21.04% beat Climb Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Enliven Therapeutics	N/A	-21.04%	-20.41%
Climb Bio	N/A	-31.45%	-30.39%

Enliven Therapeutics currently has a consensus target price of $61.80, indicating a potential upside of 83.76%. Climb Bio has a consensus target price of $21.64, indicating a potential upside of 100.89%. Given Climb Bio's stronger consensus rating and higher probable upside, analysts plainly believe Climb Bio is more favorable than Enliven Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enliven Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
Climb Bio	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	3 Strong Buy rating(s)	3.07

In the previous week, Enliven Therapeutics and Enliven Therapeutics both had 5 articles in the media. Climb Bio's average media sentiment score of 0.27 beat Enliven Therapeutics' score of 0.08 indicating that Climb Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Enliven Therapeutics	0 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Climb Bio	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Climb Bio beats Enliven Therapeutics on 8 of the 13 factors compared between the two stocks.

How does Climb Bio compare to Ultragenyx Pharmaceutical?

Ultragenyx Pharmaceutical (NASDAQ:RARE) and Climb Bio (NASDAQ:CLYM) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, earnings, profitability, institutional ownership, media sentiment, analyst recommendations, valuation and risk.

97.7% of Ultragenyx Pharmaceutical shares are held by institutional investors. Comparatively, 69.8% of Climb Bio shares are held by institutional investors. 5.2% of Ultragenyx Pharmaceutical shares are held by company insiders. Comparatively, 2.6% of Climb Bio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Climb Bio has lower revenue, but higher earnings than Ultragenyx Pharmaceutical. Climb Bio is trading at a lower price-to-earnings ratio than Ultragenyx Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ultragenyx Pharmaceutical	$673M	3.16	-$575M	-$6.11	N/A
Climb Bio	N/A	N/A	-$59.85M	-$0.78	N/A

In the previous week, Ultragenyx Pharmaceutical had 3 more articles in the media than Climb Bio. MarketBeat recorded 8 mentions for Ultragenyx Pharmaceutical and 5 mentions for Climb Bio. Ultragenyx Pharmaceutical's average media sentiment score of 0.47 beat Climb Bio's score of 0.27 indicating that Ultragenyx Pharmaceutical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ultragenyx Pharmaceutical	4 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Climb Bio	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Ultragenyx Pharmaceutical has a beta of 0.37, indicating that its stock price is 63% less volatile than the broader market. Comparatively, Climb Bio has a beta of 0.09, indicating that its stock price is 91% less volatile than the broader market.

Ultragenyx Pharmaceutical presently has a consensus price target of $59.56, indicating a potential upside of 175.88%. Climb Bio has a consensus price target of $21.64, indicating a potential upside of 100.89%. Given Ultragenyx Pharmaceutical's higher possible upside, equities analysts plainly believe Ultragenyx Pharmaceutical is more favorable than Climb Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ultragenyx Pharmaceutical	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.82
Climb Bio	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	3 Strong Buy rating(s)	3.07

Climb Bio has a net margin of 0.00% compared to Ultragenyx Pharmaceutical's net margin of -91.03%. Climb Bio's return on equity of -31.45% beat Ultragenyx Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ultragenyx Pharmaceutical	-91.03%	-1,024.42%	-45.78%
Climb Bio	N/A	-31.45%	-30.39%

Summary

Ultragenyx Pharmaceutical beats Climb Bio on 9 of the 16 factors compared between the two stocks.

How does Climb Bio compare to Kodiak Sciences?

Climb Bio (NASDAQ:CLYM) and Kodiak Sciences (NASDAQ:KOD) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, media sentiment, profitability, earnings and valuation.

Climb Bio presently has a consensus target price of $21.64, indicating a potential upside of 100.89%. Kodiak Sciences has a consensus target price of $42.14, indicating a potential upside of 42.33%. Given Climb Bio's stronger consensus rating and higher possible upside, equities analysts plainly believe Climb Bio is more favorable than Kodiak Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Climb Bio	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	3 Strong Buy rating(s)	3.07
Kodiak Sciences	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Climb Bio has a beta of 0.09, suggesting that its share price is 91% less volatile than the broader market. Comparatively, Kodiak Sciences has a beta of 2.21, suggesting that its share price is 121% more volatile than the broader market.

Climb Bio's return on equity of -31.45% beat Kodiak Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Climb Bio	N/A	-31.45%	-30.39%
Kodiak Sciences	N/A	-253.85%	-81.48%

Climb Bio is trading at a lower price-to-earnings ratio than Kodiak Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Climb Bio	N/A	N/A	-$59.85M	-$0.78	N/A
Kodiak Sciences	N/A	N/A	-$229.97M	-$4.17	N/A

In the previous week, Climb Bio had 2 more articles in the media than Kodiak Sciences. MarketBeat recorded 5 mentions for Climb Bio and 3 mentions for Kodiak Sciences. Kodiak Sciences' average media sentiment score of 0.51 beat Climb Bio's score of 0.27 indicating that Kodiak Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Climb Bio	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Kodiak Sciences	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

69.8% of Climb Bio shares are owned by institutional investors. Comparatively, 89.1% of Kodiak Sciences shares are owned by institutional investors. 2.6% of Climb Bio shares are owned by insiders. Comparatively, 45.9% of Kodiak Sciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Climb Bio beats Kodiak Sciences on 9 of the 14 factors compared between the two stocks.

Get Climb Bio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CLYM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CLYM vs. The Competition

Export

Metric	Climb Bio	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$604.12M	$3.34B	$6.49B	$11.99B
Dividend Yield	N/A	2.30%	2.67%	5.57%
P/E Ratio	-13.81	18.61	23.92	23.74
Price / Sales	N/A	298.43	507.57	108.00
Price / Cash	N/A	51.45	26.99	37.25
Price / Book	3.21	8.04	10.28	6.78
Net Income	-$59.85M	$23.89M	$3.57B	$337.51M
7 Day Performance	-8.73%	-5.97%	-1.43%	-2.72%
1 Month Performance	-5.28%	2.78%	3.27%	1.87%
1 Year Performance	674.82%	36.26%	23.37%	26.60%

Climb Bio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CLYM Climb Bio	3.1094 of 5 stars	$10.77 +2.1%	$21.64 +100.9%	+659.0%	$604.12M	N/A	N/A	9	Analyst Forecast Gap Up High Trading Volume
IMNM Immunome	3.634 of 5 stars	$21.83 -3.1%	$33.17 +51.9%	+103.5%	$2.47B	$6.94M	N/A	40
ADPT Adaptive Biotechnologies	3.1633 of 5 stars	$15.15 -0.3%	$19.57 +29.2%	+67.5%	$2.42B	$276.98M	N/A	790	Positive News
ELVN Enliven Therapeutics	2.8426 of 5 stars	$39.57 -2.7%	$58.40 +47.6%	+67.4%	$2.41B	N/A	N/A	50	News Coverage
RARE Ultragenyx Pharmaceutical	2.8497 of 5 stars	$23.94 +2.9%	$59.56 +148.8%	-41.1%	$2.36B	$673M	N/A	1,371	Analyst Upgrade Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CLYM) was last updated on 6/8/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Climb Bio (CLYM) Competitors

CLYM vs. IMNM, ADPT, ELVN, RARE, and KOD

How does Climb Bio compare to Immunome?

Summary

How does Climb Bio compare to Adaptive Biotechnologies?

Summary

How does Climb Bio compare to Enliven Therapeutics?

Summary

How does Climb Bio compare to Ultragenyx Pharmaceutical?

Summary

How does Climb Bio compare to Kodiak Sciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CLYM vs. The Competition

Climb Bio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Climb Bio (CLYM) Competitors

CLYM vs. IMNM, ADPT, ELVN, RARE, and KOD

How does Climb Bio compare to Immunome?

Is IMNM or CLYM more profitable?

Do analysts recommend IMNM or CLYM?

Do institutionals & insiders hold more shares of IMNM or CLYM?

Does the media refer more to IMNM or CLYM?

Which has more risk and volatility, IMNM or CLYM?

Which has stronger valuation and earnings, IMNM or CLYM?

Summary

How does Climb Bio compare to Adaptive Biotechnologies?

Do analysts recommend CLYM or ADPT?

Is CLYM or ADPT more profitable?

Which has preferable valuation & earnings, CLYM or ADPT?

Do institutionals & insiders believe in CLYM or ADPT?

Does the media refer more to CLYM or ADPT?

Which has more volatility & risk, CLYM or ADPT?

Summary

How does Climb Bio compare to Enliven Therapeutics?

Which has more risk & volatility, ELVN or CLYM?

Do insiders & institutionals have more ownership in ELVN or CLYM?

Which has better valuation & earnings, ELVN or CLYM?

Is ELVN or CLYM more profitable?

Do analysts rate ELVN or CLYM?

Does the media prefer ELVN or CLYM?

Summary

How does Climb Bio compare to Ultragenyx Pharmaceutical?

Do insiders and institutionals believe in RARE or CLYM?

Which has better earnings & valuation, RARE or CLYM?

Does the media refer more to RARE or CLYM?

Which has more volatility and risk, RARE or CLYM?

Do analysts prefer RARE or CLYM?

Is RARE or CLYM more profitable?

Summary

How does Climb Bio compare to Kodiak Sciences?

Do analysts rate CLYM or KOD?

Which has more volatility and risk, CLYM or KOD?

Is CLYM or KOD more profitable?

Which has better valuation and earnings, CLYM or KOD?

Does the media refer more to CLYM or KOD?

Do insiders & institutionals believe in CLYM or KOD?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CLYM vs. The Competition

Climb Bio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools